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Abstract. In recent years, oncolytic viruses have attracted 
increasing interest due to their potent antitumor effects. 
Luteolin, a natural product, has additionally been observed 
to exhibit various pharmacological antitumor activities. 
Previously, a novel dual-targeting oncolytic adenovirus, 
complement decay-accelerating factor (CD55)-tumor 
necrosis factor ligand superfamily member 10 (TRAIL), was 
constructed, which exhibited significant growth inhibitory 
effects in various types of tumor cell. The present study inves-
tigated whether the combination of luteolin and CD55-TRAIL 
was able to exert a synergistic antitumor effect in colorectal 
carcinoma (CRC) cells. The cytotoxicity and tumor cell apop-
tosis mediated by combination treatment in CRC cells were 
detected via an MTT assay, Hoechst staining and western 
blotting, respectively. Tumor growth in vivo was examined in 
a CRC mouse xenograft model following various treatments. 
The results demonstrated that the addition of luteolin enhanced 
oncolytic adenovirus‑mediated enhanced green fluorescent 
protein, early region 1A and TRAIL expression. The combina-
tion of CD55-TRAIL with luteolin synergistically inhibited 
tumor growth and promoted CRC cellular apoptosis in vitro 
and in vivo. Additionally, the combination of CD55-TRAIL 
with luteolin significantly decreased cytotoxicity in lung/bron-
chial normal epithelial cells, compared with single treatment. 
Therefore, the combination of CD55-TRAIL with luteolin may 
be a novel efficient therapeutic strategy for CRC in the future.
Introduction
Colorectal cancer (CRC) has become a major global threat to 
health. According to a 2012 report, 1.4 million people were 
diagnosed with colorectal cancer worldwide; these cases 
accounted for 9.7% of the total number of cancer cases glob-
ally (1). Therefore, it is of importance that a novel and effective 
therapy for CRC be developed.
As a promising therapy, oncolytic viruses, including condi-
tional replication oncolytic adenovirus (OA) and the OncoPox, 
replicate in and eventually lyse tumor cells (2). Cancer-targeting 
gene-viro-therapy (CTGVT), using oncolytic viral vectors 
carrying an antitumor gen, has been demonstrated to enhance 
the antitumor effects of oncolytic viruses (3-7).
A CTGVT using the carcinoembryonic antigen (CEA) 
promoter to regulate early region 1A (E1A) and carrying 
tumor necrosis factor ligand superfamily member 10 (TRAIL) 
was previously developed. TRAIL belongs to the tumor 
necrosis factor superfamily, which display antitumor effects 
by activating the death receptors in tumor cells to induce apop-
tosis (8,9). Oncolytic virus-mediated TRAIL has displayed 
antitumor effects in hepatocellular carcinoma (10,11), 
CRC (12-15), lung adenocarcinoma (16) and gastric carci-
noma (17). Based on the tumor specific carcinoembryonic 
antigen (CEA), Ad·CEA·E1A·E1B (Δ55)-TRAIL [complement 
decay-accelerating factor (CD55)-TRAIL] was constructed, 
which used the CEA promoter instead of the native E1A 
promoter to improve tumor cell targeting and carried the 
TRAIL gene (11).
Luteolin (3',4',5,7-tetrahydroxyflavone) is a natural 
substance obtained from fruits, vegetables and certain 
medicinal plants (18). Previous studies have reported that 
luteolin is able to suppress tumor growth by inducing 
tumor cell apoptosis, cell cycle arrest, and anti angiogen-
esis (19-24). Luteolin may specifically inhibit tumor growth 
in CRC by activating nuclear factor erythroid 2-related factor 
2 signaling (25). The combination of luteolin and TRAIL has 
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been shown to promote apoptosis in bladder (26) and cervical 
cancer cells (27).
In the present study, the antitumor effect of co-treatment 
with luteolin and CD55-TRAIL were examined in CRC cells, 
and it was observed that the combination markedly decreased 
CRC progression in vitro and in vivo.
Materials and methods
Cells and culture. 293 cells were obtained from Microbix 
Biosystems, Inc. (Mississauga, ONT, Canada). The human 
colorectal cancer cell lines HT-29, SW620 and SW480, and the 
human normal lung/bronchial normal epithelial cells Beas-2B, 
were acquired from the Type Culture Collection of the Chinese 
Academy of Sciences (Shanghai, China). 293 cells and Beas-2B 
cells were cultured in Dulbecco's modified Eagle's medium 
(DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA), supplemented with 10% heat-inactivated fetal 
bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). 
The other cell lines, HT-29, SW620 and SW480, were cultured 
in DMEM supplemented with 5% FBS. All cells were cultured 
in a 5% CO2 humidified incubator at 37˚C.
Generation and purification of the oncolytic virus. The OA 
CD55-TRAIL was constructed in a previous study (11). The 
CD55‑TRAIL was amplified by infecting 293 cell cultures. 
The virus was collected by CsCl gradient centrifugation, 
followed by dialysis. Viral titer was determined by 50% tissue 
culture infective dose (TICD50) analysis in 293 cells (11).
Cell viability assay. Cells (5,000) were seeded into 96-well 
plates and cultured for 24 h. The culture medium was subse-
quently replaced with medium containing CD55-TRAIL 
[5 multiplicity of infection (MOI), 10 MOI, 15 MOI], luteolin 
(25 µM) (Beyotime Institute of Biotechnology, Haimen, 
China), or a combination of CD55-TRAIL and luteolin. 
Following incubation for approximately 24, 48, 72 and 96 h, 
MTT (0.5 mg/ml) was added to each well. Following 4 h 
incubation, the cell supernatant was completely removed and 
150 ml dimethyl sulfoxide was added to each well. Following 
mixing thoroughly, the 96-well plates were read by a micro-
plate reader at a wavelength of 490 nm (Tecan Group, Ltd., 
Mannedorf, Switzerland). The effect of combination treat-
ment was evaluated using CalcuSyn version 2.1 (Biosoft, 
Cambridge, UK).
Detection of green fluorescent protein. A total of 5x104 cells 
were seeded into 6-well plates and were left to attach over-
night. The cells were treated with CD55-EGFP (15 MOI) or a 
combination of CD55-TRAIL and luteolin (25 µM). Following 
48 h incubation, the cells were subsequently observed under a 
fluorescence microscope (0.2 mm fields; magnification, x200; 
IX71-22FL/PH, Olympus Corporation, Japan).
Apoptotic cell staining. A total of 5x104 cells were seeded 
into 6-well plates and were left to attach overnight. The cells 
were treated with CD55-TRAIL (15 MOI), luteolin (25 µM), 
or a combination of CD55-TRAIL and luteolin. Following 
48 h incubation, the cells were incubated in Hoechst 33342 
(Beyotime Institute of Biotechnology) for 10 min, and washed 
twice with PBS. The cells were subsequently observed under a 
fluorescence microscope (0.2 mm fields; magnification, x200; 
IX71-22FL/PH, Olympus Corporation, Japan).
Western blot analysis. A total of 5x105 cells were seeded into 
6-well plates and were left to attach overnight. The cells were 
treated with CD55-TRAIL (15 MOI), luteolin (25 µM), or a 
combination of CD55-TRAIL and luteolin. After 72 h, the 
cells were removed and lysed with radioimmunoprecipitation 
assay buffer (Beyotime Institute of Biotechnology, Shanghai, 
China) containing protease inhibiters to collect protein. The 
concentration of proteins collected was determined using the 
Pierce bicinchoninic acid protein assay kit (Thermo Fisher 
Scientific, Inc.). Subsequently, the protein (20 µg) was sepa-
rated using 6% SDS-PAGE to detect cleaved poly-ADP-ribose 
polymerase (PARP; cat. no. 5625) and PARP and the protein 
(20 µg) were separated using 12% SDS-PAGE to detect 
GAPDH (cat. no. 51332), procaspase-9 (cat. no. 9508), cleaved 
caspase-9 (cat. no. 7237), E3 ubiquitin-protein ligase XIAP 
(XIAP; cat. no. 14334), E1A (cat. no. sc374663) and TRAIL 
(cat. no. 3219) and transferred onto a polyvinylidene difluoride 
membrane. The membranes were blocked with 5% non-fat 
dried milk at room temperature for 2 h and incubated in 
primary antibodies [GAPDH, procaspase-9, cleaved caspase-9, 
cleaved poly-ADP-ribose polymerase (PARP), PARP, E3 
ubiquitin-protein ligase XIAP (XIAP), E1Aand TRAIL] over-
night at 4˚C. The working dilution of all primary antibodies 
was 1:1,000. The membranes of GAPDH, procaspase-9 and 
E1A were subsequently incubated in the corresponding mouse 
secondary antibody (cat. no. 10230269) and the membranes 
of cleaved caspase-9 cleaved PARP, PARP and TRAIL were 
subsequently incubated in corresponding rabbit secondary 
antibody (cat. no. 10245169). the working dilution of all 
secondary are the ratio of 1:5,000 and the all membranes are 
incubated at room temperature for 2 h. Protein expression was 
detected using the Odyssey infrared imaging system (LI-COR 
Biosciences, Lincoln, NE, USA). All antibodies, except 
the E1A antibodies, were purchased from Cell Signaling 
Technology, Inc. (Danvers, MA, USA). The E1A antibodies 
were obtained from Santa Cruz Biotechnology, Inc. (Dallas, 
TX, USA). The mouse and rabbit secondary antibodies were 
obtained from PerkinElmer, Inc. (Waltham, MA, USA).
Flow cytometric analysis. A total of 5x105 cells were seeded 
into 6-well plates and were left to attach overnight. The cells 
were treated with CD55-TRAIL (15 MOI), luteolin (25 µM), 
or a combination of CD55-TRAIL and luteolin. After 48 h, 
the cells were trypsinized and harvested. Aliquots of cells 
were resuspended in 500 ml binding buffer and stained with 
annexin V fluorescein isothiocyanate/propidium iodide (BD 
Biosciences, San Jose, CA, USA), according to the manufac-
turer's protocol. The cells were immediately identified using 
fluorescence‑activated cell sorting (BD Biosciences).
Animals. Animal studies followed the regulations and stan-
dards set by the US Department of Agriculture and the National 
Institutes of Health. A total of 24 female BALB/c nude mice 
(4 weeks old; mean body weight 18 g) were purchased from 
the Zhejiang Chinese Medical University (Hangzhou, China) 
and housed at 28˚C, 40‑60% humidity and a 12‑h light/dark 
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cycle. The experimental protocol was approved by the Animal 
Care and Welfare Committee of Zhejiang Chinese Medical 
University (Hangzhou, China).
Tumor xenograft. A total of 8x106 HT-29 cells were injected 
subcutaneously into the right flank of nude mice. When the 
tumor had grown to a diameter of 400-600 mm3, the mice 
were divided randomly into 4 groups and were injected 
with PBS (vehicle), luteolin (50 mg/kg) alone, CD55-TRAIL 
(2x109 plaque-forming units) alone or CD55-TRAIL and lute-
olin. Subsequent to the injection, the tumor size was measured 
using a Vernier calliper every 5 days.
Histopathology, immunohistochemistry (IHC) and terminal 
deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay. The liver, kidney, spleen and tumor tissues 
were harvested and fixed in 5% paraformaldehyde at room 
temperature for 48 h, dehydrated with gradient increasing 
ethanol concentrations and embedded in paraffin wax, and 
were cut into 5-mm sections. The sections were stained with 
hematoxylin and eosin at room temperature for 5 min for 
histological analysis. The sections were blocked with 5% BSA 
at room temperature for 20 min and subsequently incubated 
in anti-TRAIL antibodies (3219; Cell Signaling Technology, 
Inc.) overnight at 4˚C, followed by avidin‑biotin‑peroxidase 
complex reagents (Vector Laboratories, Inc., Burlingame, CA, 
USA) for the IHC analysis. The working dilution of anti-TRAIL 
antibodies was 1:300. Hematoxylin was used as a counterstain 
at room temperature for 5 min. The in‑situ apoptosis detection 
kit (Sino-American Biotechnology Co., Luoyang, China) was 
used to stain apoptotic cell tumor tissue sections, according to 
the manufacturer's protocol, for the TUNEL assay. All sections 
were counterstained with hematoxylin at room temperature for 
5 min. All sections were subsequently observed under a micro-
scope (0.2 mm fields; magnification, x200; IX71‑22FL/PH, 
Olympus Corporation, Japan).
Statistical analysis. All experiments were repeated three 
times and data are presented as the mean ± standard deviation. 
Statistical analysis was performed using GraphPad Prism 6 
Figure 1. Cytopathic effect of the combining CD55-TRAIL with luteolin in colorectal cancer and normal cells. (A) Cell viability was examined via an MTT 
assay. (B) Beas-2B cells were treated with luteolin (25 µM) or the combination of CD55-TRAIL (15 MOI) with luteolin (25 µM). (C) HT-29 cells and Beas-2B 
cells were treated with luteolin (80 µM) or the combination of CD55-TRAIL (15 MOI) with luteolin (25 µM). All data are presented as the mean ± standard 
deviation. n=3. **P<0.01; ***P<0.001. NS, not significant; CD55, complement decay‑accelerating factor; TRAIL, tumor necrosis factor ligand superfamily 
member 10; MOI, multiplicity of infection.
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version is 6.01 (GraphPad Software, Inc., La Jolla, CA, USA) 
for a Student's t test. P<0.05 was considered to indicate a statis-
tically significant difference.
Results
CD55‑TRAIL with luteolin reduces the cell viability of CRC 
cells. The oncolytic virus CD55-TRAIL was constructed by 
inserting a TRAIL gene-expressing cassette into CD55. TRAIL 
gene expression was regulated by the human cytomegalovirus 
immediate-early promoter. CEA protein expression in HT-29 
and SW620 cells was detected via western blotting to ensure 
the replication of CD55-TRAIL.
In order to evaluate the antitumor effect of CD55-TRAIL 
and luteolin in vitro, CRC cell lines SW620, SW480 and HT-29 
were infected with CD55-TRAIL (at various concentrations) 
and luteolin (25 µM) (Fig. 1A) for 48 h. It was observed that, 
following treatment, cell viability significantly decreased in a 
time-dependent manner. At 96 h post-infection, cell viability 
was <30%. Treatment with CD55-TRAIL and luteolin was 
similar to luteolin alone, illustrating the decreased toxicity of 
CD55-TRAIL in normal BEAS-2B cells (Fig. 1B) at 48 h. An 
increased concentration of luteolin (80 µM), and the combina-
tion of CD55-TRAIL (15 MOI) with luteolin (25 µM), was 
used to treat HT-29 and BEAS-2B cells; in HT-29 CRC cells, 
the same cytotoxic effects were observed leading to a viability 
of <35%, although the combination treatment induced less 
toxicity in normal Beas-2B cells (>65% viability) (Fig. 1C). 
The results of the present study suggested that the combination 
of CD55-TRAIL with luteolin suppressed CRC cell prolifera-
tion with minimal toxic impact to normal cells compared with 
luteolin alone.
Luteolin enhances CD55‑mediated transgene expression 
in CRC cells. In order to detect whether the luteolin was 
able to enhance oncolytic adenovirus CD55-mediated gene 
expression, HT-29 cells were treated with CD55-enhanced 
green fluorescent protein (EGFP) (15 MOI) or CD55‑EGFP 
(15 MOI) and luteolin (25 µM). After 24 h, it was observed 
that the percentage of EGFP fluorescent cells was increased in 
HT-29 cells treated with CD55-EGFP and luteolin compared 
with CD55-EGFP alone (Fig. 2A), suggesting that luteolin 
promoted CD55-EGFP replication and EGFP expression. 
In addition, E1A and TRAIL expression was detected in 
CD55-TRAIL-infected HT-29 cells. The results demonstrated 
that combination treatment with CD55-TRAIL and luteolin 
led to increased E1A and TRAIL expression compared with 
CD55-TRAIL alone or luteolin alone (Fig. 2B), indicating 
that luteolin was able to enhance CD55-mediated associated 
protein expression.
Figure 2. Luteolin promotes CD55-TRAIL replication and associated gene expression. (A) Colorectal cancer HT-29 cells were treated with CD55-Trail 
(15 MOI; a and b), or with CD55‑Trail (15 MOI) plus luteolin (25 µM; c and d). Images a and c were captured using a light microscope (0.2 mm fields; magni-
fication, x200); b and d were captured using a fluorescence microscope (0.2 mm fields; magnification, x200). (B) E1A and TRAIL expression was detected 
by western blot analysis. (C) Cell viability was detected via an MTT assay. The quantitated data were processed using CalcuSyn software, and the CI values 
of the treatment groups are represented by X-marks. All data are presented as the mean ± standard deviation. n=3. *P<0.05, **P<0.01. CD55, complement 
decay-accelerating factor; TRAIL, tumor necrosis factor ligand superfamily member 10; MOI, multiplicity of infection; CI, combination index; E1A, early 
region 1A; EGFP, enhanced green fluorescent protein.
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In order to determine whether the antitumor effect of the 
combination therapy was synergistic or additive, the effect of 
combination treatment was evaluated using CalcuSyn. HT-29 
cells were treated with CD55-TRAIL alone at various concen-
trations, luteolin alone or a combination at the constant ratio 
of 3:5 for 48 h. The X-marks on the graph (Fig. 2C) were used 
as the combination index (CI) values. All the experimental CI 
values were <1, illustrating that the combination treatment had 
a synergistic effect (Fig. 2C).
Combination of CD55‑TRAIL with luteolin induces apop‑
tosis in cancer cells. In order to determine whether the 
antitumor effects of the combination therapy were induced 
by an enhancement of apoptosis in cancer cells, Hoechst 
33342 analysis was used to examine morphological altera-
tions indicative of apoptosis in HT-29 cells. The results 
indicated that compared with CD55-TRAIL or luteolin 
alone, the combination-treated cells displayed greater chro-
matin condensation, nuclear fragmentation and apoptotic 
body formation (Fig. 3A). Notably, normal Beas-2B cells 
exhibited few signs of apoptosis (Fig. 3A). The examina-
tion of cell death by flow cytometry of treated HT‑29 cells 
revealed that compared with 1.7% for luteolin and 3.8% for 
CD55-TRAIL, treatment with CD55-TRAIL with luteolin 
resulted in a significantly increased percentage of apoptotic 
cells at 9.8% (Fig. 3B). Therefore, combination treatment 
induced apoptosis to a greater degree compared with each 
treatment alone.
In order to further elucidate the underlying mechanism of 
cellular apoptosis, expression of the caspase signaling pathway 
proteins was detected by western blot analysis. Procaspase-9, 
cleaved caspase-9, PARP, cleaved PARP and XIAP were 
detected in HT-29 cells treated for 48 h (Fig. 3C). There was 
a significant decrease in the expression of anti-apoptosis 
proteins procaspase-9 and PARP, and an increase in the 
pro-apoptosis proteins cleaved caspase-9 and cleaved PARP, 
in cells treated with the combination therapy compared with 
the other treatments. The decreased expression of XIAP with 
the combination treatment compared with other apoptosis 
treatment significantly increased the effect of apoptosis. The 
results of the present study suggested that the combination 
treatment enhanced cellular apoptosis via activation of the 
caspase apoptosis pathway.
Antitumor efficacy of the combination of CD55‑TRAIL with 
luteolin in vivo. In order to further examine their antitumor 
efficacy in vivo, the HT-29 xenograft model was established in 
nude mice. Treatment with luteolin, CD55-TRAIL or a combi-
nation of the two for 48 h was applied subcutaneously to the 
right flank of the mice. As solid tumors may not exceed 20 mm 
diameter for ethical reasons, animals were sacrificed at day 30. 
The results demonstrated that the tumor volume in the groups 
Figure 3. Inducing apoptosis via the combination of CD55-TRAIL and luteolin. (A) After 48 h, nuclear fragmentation (arrows) was observed in HT-29 (a-d) 
and Beas‑2B (e‑h) cells using Hoechst staining under an inverted fluorescence microscope (0.2 mm fields; magnification, x200). The a and e were untreated. 
The b and f were treated with luteolin. The c and g were treated with CD55-TRAIL. The d and h were treated with the combination of CD55-TRAIL 
with luteolin. (B) The percentage of apoptotic cells was detected using flow cytometric analysis. The data are presented as the mean ± standard deviation. 
n=3. *P<0.05. (C) Apoptosis-associated protein expression was detected by western blotting. GAPDH was used as the internal control. CD55, complement 
decay-accelerating factor; TRAIL, tumor necrosis factor ligand superfamily member 10; XIAP, E3 ubiquitin-protein ligase XIAP; PARP; poly-ADP-ribose 
polymerase.
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receiving PBS, luteolin or CD55-TRAIL reached ~3,761 mm3, 
~3,415 mm3 and ~3,072 mm3, respectively, within 30 days; 
the combination of CD55‑TRAIL with luteolin significantly 
impeded the growth of the tumor, with a tumor volume of 
~1,780 mm3 representing a 58% inhibition of tumor growth 
(Fig. 4A). Additionally, after 25 days, the tumor volume in 
the combination treatment was decreased, suggesting that the 
combination treatment has better anti-tumor effect.
Examination of TRAIL and cell death-associated protein 
TUNEL expression by IHC analysis of tumor tissues 20 days 
subsequent to drug treatment revealed that the expression of 
TUNEL was increased in animals receiving combination 
treated cells, compared with other mice (Fig. 4B). Hematoxylin 
and eosin staining demonstrated that the combination of 
CD55-TRAIL with luteolin caused more severe cytopathic 
effects in tumor tissues compared with each therapy alone 
(Fig. 4B). In addition, the liver, kidney and spleen tissues 
without toxic effects were indicated by hematoxylin and eosin 
staining, implying that little to no cell damage or apoptosis had 
occurred in these tissues (Fig. 4C). IHC staining demonstrated 
that the TRAIL protein was highly expressed in tumor tissue 
following treatment with the combination of CD55-TRAIL 
and luteolin (Fig. 4B).
Discussion
Luteolin functions as a tumor suppressor by inducing tumor 
cell apoptosis, cell cycle arrest, and antiangiogenesis (19-24). 
However, these effects are accompanied by severe side 
effects which may cause damage to normal cells. In addition, 
long-term use of chemotherapy drugs may cause drug resis-
tance in the tumor, leading to an increase in the dose of the 
drug, thereby resulting in more serious side effects. A number 
of combined therapeutic strategies have demonstrated fewer 
negative effects (28,29). Therefore, a combination strategy 
which may markedly decrease these severe side effects may 
provide a potentially promising treatment for CRC.
The present study revealed the potent antitumor effect of 
oncolytic adenovirus CD55-TRAIL with luteolin on CRC 
cells in vitro and in vivo, while minimizing cytotoxicity to 
normal cells. The combination therapy significantly and syner-
gistically inhibited CRC cell proliferation. This inhibition 
was induced in part by the enhancement of CD55-mediated 
TRAIL expression in CRC cells by luteolin. The combina-
tion of CD55-TRAIL with luteolin additionally decreased the 
toxicity of luteolin in lung/bronchial normal epithelial cells. It 
was demonstrated that the combination of CD55-TRAIL with 
luteolin reduced the dose of luteolin required to elicit the same 
antitumor effect as luteolin alone.
The results of the present study demonstrated that the 
combination treatment induced antitumor effects by enhancing 
apoptosis, evidenced by an increase in chromatin condensa-
tion, nuclear fragmentation, the formation of apoptotic bodies 
and the expression of caspase apoptotic pathway proteins 
in CRC cells. In addition, compared with each treatment 
individually, the combination of CD55-TRAIL with luteolin 
decreased the expression of the caspase inhibitor gene XIAP 
in order to activate the caspase apoptotic pathway. This finding 
was consistent with a previous report showing that the combi-
nation of TRAIL with luteolin inhibited the expression of the 
XIAP gene to activate the caspase apoptotic pathway in HeLa 
cells (30). The distinct molecular mechanism of the combi-
nation treatment strategy remains to be further elucidated in 
future studies.
Progress has been made in the field of OAs, including the 
CTGVT strategy and the use of specific promoters instead of 
the E1A promoter to improve targeting. However, OAs, due 
to their heterogeneity, may induce an inflammatory response 
following infection of the tumor tissue and elicit antiviral 
effects. In addition, the bioavailability of oncolytic adeno-
viruses is low when administered by intravenous injection. 
Further studies are required to resolve these issues. Thus, 
OAs have been considered less as an individual treatment for 
tumors, and more as a combination therapy, including OAs 
Figure 4. Antitumor efficacy of the combination of CD55-TRAIL with 
luteolin in vivo. (A) The tumor volume was measured every 5 days using the 
formula V (mm3)=1/2xlength xwidth2. Data are presented as the mean ± stan-
dard deviation, n=5. ***P<0.001. (B) The apoptosis of tumor sections was 
assayed using TUNEL staining. The cellular necrotic areas in the tumors 
were detected using HE staining. The TRAIL expression in tumor tissues 
was detected by immunohistochemical staining. (C) The toxicity to liver, 
kidney and spleen tissues was detected by HE staining. Magnification, x200. 
HE, hematoxylin and eosin; CD55, complement decay-accelerating factor; 
TRAIL, tumor necrosis factor ligand superfamily member 10; TUNEL, 
terminal deoxynucleotidyl transferase dUTP nick end labeling.
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combined with nanomaterials (31,32), immune cells (33,34) 
and chemotherapy drugs (30,31), which have exhibited an 
improved therapeutic effect compared with oncolytic viruses 
alone. Additionally, previous studies have focused on the iden-
tification of tumor biomarkers based on microRNAs (35,36), 
which may provide the possibility of improving the antitumor 
effect of oncolytic virotherapy.
The results of the present study demonstrated that the 
combined use of luteolin and CD55-TRAIL had a potent anti-
tumor effect, and that the antitumor effect of CD55-TRAIL 
was synergized by luteolin in CRC cells with reduced toxicity 
to normal epithelial cells. Additionally, this combination 
resulted in a strong apoptotic effect in CRC cells in vitro and 
in vivo. In conclusion, the combination of CD55-TRAIL with 
luteolin provided a potentially effective clinical therapy for 
CRC.
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